NCT06293833 2024-03-05
ZORALCS
University Hospital, Antwerp
Phase NA Unknown
Clinical Trials
117 trialsNCT05957510 2024-02-22
Safety and Efficacy Evaluation of Serplulimab Plus Chemo in SCLC Transformed From EGFR-mutated NSCLC After Treatment
Guangdong Association of Clinical Trials
Phase 2 Unknown
NCT05829057 2024-02-13
The IIT Study of Evaluation of P-IL-2 Single Agent and With Anti-PD-1
Zhejiang University
Phase 1 Unknown
NCT05092412 2024-01-12
Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC
Sichuan University
Phase 2 Unknown
NCT05296603 2024-01-10
Efficacy and Biomarker Explanation of IBI-322 Plus Lenvatinib on Extensive Stage Small Cell Lung Cancer
Hunan Province Tumor Hospital
Phase 2 Unknown
NCT06187740 2024-01-09
Thoracic Consolidation Radiotherapy for ES-SCLC Treated With Chemo-immunotherapy
Fudan University
Phase 1 Unknown
NCT04985851 2023-12-01
To Evaluate the Efficacy of Durvalumab + Anlotinib in Terms of OS and PFS.
Shanghai Chest Hospital
Phase NA Unknown
NCT04253145 2023-11-18
Study to Assess Safety,Tolerability,Efficacy of PM01183 and Atezolizumab in Patients w/ Advanced Small Cell Lung Cancer.
Fundacion Oncosur
Phase 1/2 Unknown
NCT05228496 2023-09-26
A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Sitravatinib as Maintenance Therapy for ES-SCLC
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT05975944 2023-08-04
Study of Selinexor Combined With Olaparib in Relapsed/Refractory Extensive Stage Small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 1/2 Unknown
NCT05731518 2023-07-14
SC0245 and Irinotecan in Treating Patients With Relapsed Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Biocity Biopharmaceutics Co., Ltd.
Phase 1/2 Unknown
NCT05901584 2023-06-18
Cadonilimab (AK104) With or Without CT as 2rd Line Treatment for ES-SCLC
Second Affiliated Hospital of Zunyi Medical University
Phase 2 Unknown
NCT05780307 2023-06-07
IMM2520, a PD-L1 and CD47 Bispecific Antibody in Patients With Advanced Solid Tumors
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Phase 1 Unknown
NCT03568097 2023-06-02
PAVE
Hellenic Cooperative Oncology Group
Phase 2 Unknown
NCT05886075 2023-06-02
A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Advanced Solid Tumors
Shanghai Yunying Medical Technology
Phase EARLY_PHASE1 Unknown
NCT00526396 2023-03-24
STAD-1
National Cancer Institute, Naples
Phase 3 Unknown
NCT05429866 2023-03-08
Immunological Variables Associated to ICI Toxicity in Cancer Patients
Jules Bordet Institute
Phase 2 Unknown
NCT05668767 2022-12-30
Surufatinib in Combination of Durvalumab and EP/EC in the Firstly-line Treatment of ES-SCLC
Beijing Chest Hospital
Phase 2 Unknown
NCT05595889 2022-11-29
Surufatinib Combined With Irinotecan as a Second-line Treatment for Small Cell Lung Cancer
Fujian Cancer Hospital
Phase 2 Unknown
NCT04996771 2022-11-14
Surufatinib Combined With Chemotherapy Plus Toripalimab or Not in the Treatment of Small Cell Lung Cancer
Sun Yat-sen University
Phase 1/2 Unknown
NCT00100256 2022-11-07
Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy
Andarix Pharmaceuticals
Phase 1/2 Unknown
NCT05205421 2022-08-05
A Study of Oncolytic Virus Injection (RT-01) in Patients With Extensive-Stage Small Cell Lung Cancer
The First Affiliated Hospital of Bengbu Medical University
Phase 1 Unknown
NCT05027100 2022-07-01
Tislelizumab Combined With Anlotinib and 2-cycles Irinotecan as Second Line Treatment of SCLC
Guangzhou University of Traditional Chinese Medicine
Phase NA Unknown
NCT05354700 2022-05-04
A Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy in Patients With Extensive Small Cell Lung Cancer
Shanghai Henlius Biotech
Phase 2 Unknown
NCT05162196 2022-05-02
The Efficacy and Safety of Radiotherapy Plus Niraparib and Toripalimab in Patients With Recurrent Small Cell Lung Cancer
Wuhan University
Phase 2 Unknown
NCT03711305 2022-04-18
Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown
NCT04660097 2022-04-12
Alotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer
Henan Cancer Hospital
Phase 2 Unknown
NCT01441349 2022-04-06
Irinotecan/Cisplatin With or Without Simvastatin in Chemo-naive Patients With Extensive Disease-small Cell Lung Cancer
National Cancer Center, Korea
Phase 2 Unknown
NCT05299255 2022-03-28
Utidelone in Third-line and Above Treatment of Small Cell Lung Cancer
Henan Cancer Hospital
Phase 2 Unknown
NCT05245994 2022-02-18
An Open Label, Multicenter Phase 2 Study of Durvalumab (MEDI4736) + Olaparib as Maintenance Therapy in Chinese
Sun Yat-sen University
Phase 2 Unknown
NCT02446704 2022-02-07
Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy
Massachusetts General Hospital
Phase 1/2 Unknown
NCT05191849 2022-01-14
Circulating EV Long RNA Profiles in SCLC
Fudan University
Phase NA Unknown
NCT04450043 2022-01-13
The Transitions Project: Supporting Adults During the Shift From Cancer Treatment to Surveillance
Massachusetts General Hospital
Phase NA Unknown
NCT05158491 2022-01-05
Safety, Tolerability and Preliminary Efficacy of JK1201I in Patients With SCLC
JenKem Technology Co., Ltd.
Phase 1/2 Unknown
NCT04901754 2021-12-08
CAMERA
Henan Cancer Hospital
Phase 2 Unknown
NCT04985201 2021-08-09
Combined Simvastatin and Irinotecan in Treating ES-SCLC Patients Relapsed From 1st Chemotherapy
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Unknown
NCT04890795 2021-05-18
A Phase Ib / IIA Study of AL8326 in Small Cell Lung Cancer
Advenchen Laboratories, LLC
Phase 1/2 Unknown
NCT04782089 2021-03-04
Study of PD-1 Antibody and PARP Inhibitor in Extensive Stage Small Cell Lung Cancer
Qilu Hospital of Shandong University
Phase NA Unknown
NCT04691063 2021-02-26
The Study is Being Conducted to Evaluate the Efficacy and Safety of SHR-1316 in Combination With Chemo-radiotherapy in Patients With LS-SCLC.
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown
NCT04490421 2021-02-08
Camrelizumab Combined With Apatinib, Etoposide and Cisplatin Treat Small-cell Lung Cancer.
Fuzhou General Hospital
Phase 3 Unknown
NCT04740021 2021-02-05
Study of LP002 in Combination With Chemotherapy for Patients With Extensive Stage Small Cell Lung Cancer
Taizhou HoudeAoke Biomedical Co., Ltd.
Phase 2 Unknown
NCT02171325 2021-02-03
Study of Different Doses of Irinotecan and Cisplatin for First-line Extensive-stage Small-cell Lung Cancer Treatment
Guangdong Association of Clinical Trials
Phase 2 Unknown
NCT04500145 2021-02-01
Simultaneous Integrated Boost vs. Routine IMRT in Limited-stage Small-cell Lung Cancer
ChineseAMS
Phase 3 Unknown
NCT02337712 2021-01-27
Once-daily Simultaneous Modulated Accelerated Thoracic Radiotherapy in Limited Small-cell Lung Cancer
Sun Yat-sen University
Phase 2 Unknown
NCT03227016 2021-01-27
Study in Patients With SCLC of Veliparib in Combination With Topotecan
Central European Society for Anticancer Drug Research
Phase 1 Unknown
NCT04696939 2021-01-06
Combined Atezolizumab and Chemotherapy (Carboplatin Plus Etoposide) in Neoadjuvant Treating Limited-Stage Small Cell Lung Cancer Patients
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Unknown
NCT04683198 2020-12-24
Camrelizumab Combined With Apatinib ,Carboplatin and Etoposide in Participants With ES-SCLC
ChineseAMS
Phase 2 Unknown
NCT04675697 2020-12-19
Anlotinib Plus Platinum-etoposide in First-line of Extensive-stage Small-cell Lung Cancer
Xiangya Hospital of Central South University
Phase 2 Unknown
NCT04659785 2020-12-09
A Study of Fluzoparib Combined With Apatinib as Second-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer（FA-ES-SCLC）
Tianjin Medical University Second Hospital
Phase 1/2 Unknown
NCT04647357 2020-11-30
A Trial of SHR-1316 Maintenance Therapy for Limited Stage Small Cell Lung Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Unknown